ORPHA:319319
Renal medullary carcinoma
Publications
1,519
Trials
17
Interventional, condition-specific
Researchers
1,380
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
Renal medullary carcinoma is a rare, aggressive subtype of renal cell carcinoma characterized by a large, white or tan, firm, infiltrative tumor with microabscess-like foci centered in the renal medulla, typically presenting with hematuria, abdominal/flank pain, weight loss and fever. It is associated with sickle cell trait and disease and metastasis to the bones and lungs is common at time of diagnosis.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0006260
- UMLS:C4049328
- NCIT:C7572
Additional Mondo synonyms (5)
Renal Medullary Carcinoma · carcinoma of renal medulla · kidney medullary carcinoma · renal medulla carcinoma · renal medullary carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,519 matched papers (983 in last 10 years) Source
- Phenotype characterisedPresent
22 HPO annotations (e.g. Congenital nystagmus; Presenile cataracts; Hypoplasia of the fovea) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
17 matched on ClinicalTrials.gov (5 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
22
Associated phenotypes · MONDO:0006260
- Congenital nystagmus
- Presenile cataracts
- Hypoplasia of the fovea
- Visual impairment
- Remnants of the hyaloid vascular system
Showing 5 of 22 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
15
Drugs / clinical candidates · MONDO_0006260
- ATEZOLIZUMAB·phase 2
- BEVACIZUMAB·phase 2
- CEMIPLIMAB·phase 2
- DOXORUBICIN·phase 2
- GEMCITABINE·phase 2
- IPILIMUMAB·phase 2
- IXAZOMIB·phase 2
- NIVOLUMAB·phase 2
- PLATINUM·phase 2
- RELATLIMAB·phase 2
- SACITUZUMAB GOVITECAN·phase 2
- SACITUZUMAB TIRUMOTECAN·phase 2
- TAZEMETOSTAT·phase 2
- UBAMATAMAB·phase 2
- CABOZANTINIB·phase 1
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,519
1,519 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,519 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
983 in the last 10 years · low confidence
Phrase hits: 1,519 · MeSH hits: 0
Who's working on it?
1,380
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Msaouel P29 papers · 2026
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Papers in Europe PMC - 02Tannir NM25 papers · 2026
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Papers in Europe PMC - 03Genovese G13 papers · 2026
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77025.
Papers in Europe PMC - 04Rao P12 papers · 2026
Department of Pathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.
Papers in Europe PMC - 05Sheth RA8 papers · 2026
Department of Interventional Radiology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Papers in Europe PMC - 06Gao J7 papers · 2026
Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
Papers in Europe PMC - 07Karam JA7 papers · 2026
Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX; Department of Translational Molecular Pathology, Division of Pathology and Laboratory Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.
Papers in Europe PMC - 08Karki M6 papers · 2026
Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Papers in Europe PMC - 09Walker CL6 papers · 2025
Center for Precision Environmental Health, Baylor College of Medicine, Houston, TX 77030.
Papers in Europe PMC - 10Daw NC5 papers · 2026
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
17
interventional trials for this specific condition
17 interventional trials matched this specific condition name; 5 currently recruiting in our sample.
Data as of 11 September 2026
17 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 94.4th percentile).
low confidence · 94.4th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
17 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT07438626·NOT YET RECRUITING·Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma
Not reviewed·Conditions: Phase II · Sacituzumab · Tirumotecan · SMARCB1-deficient Renal Medullary Carcinoma·Matched via name phrase
- NCT06444880·RECRUITING·Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
Not reviewed·Conditions: SMARCB1-Deficient Malignancies · Epithelioid Sarcoma · Renal Medullary Carcinoma·Matched via name phrase
- NCT06161532·RECRUITING·Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
Not reviewed·Conditions: Small Cell Carcinoma of the Bladder · Small Cell Carcinoma of the Urinary Tract · Squamous Cell Carcinoma of the Bladder · Squamous Cell Carcinoma of the Urinary Tract·Matched via name phrase
- NCT03866382·RECRUITING·Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Not reviewed·Conditions: Bladder Adenocarcinoma · Bladder Clear Cell Adenocarcinoma · Bladder Mixed Adenocarcinoma · Bladder Neuroendocrine Carcinoma·Matched via name phrase
- NCT06302569·RECRUITING·Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
Not reviewed·Conditions: Bellini Carcinoma · Collecting Duct Carcinoma · Renal Medullary Carcinoma·Matched via name phrase
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 10 · after dedupe 10 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 10 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (10)
- ctis·2024-511587-93-00·Authorised·Activity of Pembrolizumab plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (REPRINT trial)
skipped — LLM skipped (--skip-llm)
- ctis·2023-510553-41-00·Cancelled·TAZEMETOSTAT ROLLOVER STUDY (TRUST): AN OPEN-LABEL, ROLLOVER STUDY
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN83576037·No longer recruiting·A phase 2, safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy study of a subcutaneous injection of BC-006 and tirzepatide in adults with obesity
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN22102770·Recruiting·A study to test the safety and effects of a New Drug (LAE103) in healthy people who are overweight or obese, and in healthy postmenopausal women. The study also looks at how LAE103 works when taken alone or together with another drug (LAE102).
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN29694121·Not yet recruiting·Semaglutide as an add-on treatment to optimise glycaemic control in children and young people with type 1 diabetes (Smile T1D)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN18176375·No longer recruiting·A phase 1, safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of a subcutaneous injection of BC-006 in adults with obesity-part 2
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN76193287·No longer recruiting·ASCEND PLUS - a research study to test whether a treatment called oral semaglutide can protect people with type 2 diabetes from heart attacks, strokes, and other health problems
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN53348826·No longer recruiting·Renal Adjuvant Multiple Arm Randomised Trial (RAMPART)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN89711766·No longer recruiting·Evaluating the effects of the novel GLP1 analogue, Liraglutide, in patients with Alzheimer's Disease (ELAD study)
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN59521990·No longer recruiting·A randomised controlled trial of colorectal polyp and cancer prevention using aspirin and resistant starch in carriers of hereditary nonpolyposis colorectal cancer
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Renal medullary carcinoma — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Renal medullary carcinoma" OR "carcinoma of renal medulla" OR "carcinoma of the renal medulla" OR "kidney medullary carcinoma" OR "renal medulla carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Renal medullary carcinoma" OR "carcinoma of renal medulla" OR "carcinoma of the renal medulla" OR "kidney medullary carcinoma" OR "renal medulla carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 17 interventional · 1 observational · 2 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1519) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T13:25:23.272Z
